Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
KAN-HER2 MRD
Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease
- NCT05388149 ↗
- Recruiting
- University Health Network, Toronto
- Focused
We haven't built an HCP commentary report on KAN-HER2 MRD (neratinib in Breast Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on KAN-HER2 MRD so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 1 | |
| Podcasts | 1 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Breast Cancer; HER2-positive Breast Cancer
- Interventions
- Neratinib
- Arms
- Neratinib Arm · Experimental
- Enrollment
- 15 (estimated)
- Primary outcomes
- Clearance of ctDNA with the addition of neratinib to trastuzumab-DM1 in patients with MRD detectable by the RaDaR assay, following standard neoadjuvant therapy, surgery, and initiation of T-DM1
- Sponsor
- University Health Network, Toronto
- Start
- Dec 6, 2022
- Primary completion
- Jul 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05388149 · updated Oct 13, 2026